Oasmia presses ahead with new water-soluble paclitaxel formulation
This article was originally published in Scrip
Executive Summary
The US FDA has granted orphan drug designation for Oasmia Pharmaceutical's Paclical (paclitaxel) for the treatment of ovarian cancer. The Swedish company hopes to achieve a 35% market share, its CEO, Julian Aleksov, told Scrip.
You may also be interested in...
Deal Watch: Appili Gets AiPharma’s Help In Advancing COVID-19 Therapy
Appili brings in AiPharma to help with US/Canadian development of Fujifilm’s potential COVID-19 preventative/therapeutic. Other recent tie-ups include CinFina/Janssen, Bone/Impant, Bayer/Gubra, Novartis/Theragnostics, Grifols/Biotest and more.
UK pharmacists warned of swine flu vaccination counterfeits
"Unscrupulous traders" are likely to begin selling Tamiflu (oseltamivir) and Relenza (zanamivir) counterfeits if the swine flu situation escalates, the Royal Pharmaceutical Society of Great Britain (RPSBG) has warned. The alert comes in a letter to pharmacists providing information on the swine flu outbreak.
EMEA's PROTECT project accepted for funding
The Innovative Medicines Initiative Joint Undertaking (IMI JU) has agreed to fund the PROTECT project (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium).